Skip to main content
  • Effect of Fibrin Matrices-containing Human Fetal Neural Stem Cell Engraftment in Rat Model of Penetrating Traumatic Brain Injury (PTBI)

    Final Number:
    599

    Authors:
    Lee Onn Chieng BS; Markus Spurlock; Shyam Gajavelli; Julia Janecki; Anil Mahavadi; Liz Quesada; Karla Rivera; Ross Bullock

    Study Design:
    Laboratory Investigation

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2016 Annual Meeting

    Introduction: Penetrating traumatic brain injury has been associated with high mortality as well as severe cognitive and motor deficits. Currently, there is no neurorestorative therapy for PTBI. Experimental models of PTBI such as the “ penetrating ballistic brain injury” (PBBI) has shown ~15-25% engraftment of human NSC’s, but cell therapy needs to address the toxic microenvironment in the lesion core. The hypothesis of this study is that survival of human neural stem cell (hNSC) in the lesion core will be improved when they are embedded within a fibrin-matrix.

    Methods: In our study, athymic Sprague-Dawley rats with unilateral PBBI were randomly assigned to groups:1) hNSC without matrix 2) hNSC with matrix. Stereotactic injection of control or fibrin-matrix embedded hNSCs into lesion core was carried out a week following PBBI. Animals were sacrificed at 2 weeks or 6 weeks endpoint. Immunohistochemistry staining and confocal microscopy was used to analyze survival, distribution, differentiation and potential tumor formation.

    Results: Histological analysis revealed cell survival and distribution in the group with fibrin scaffold and differentiation was greater than in the group without matrix at both time points post transplantation. The transplants seem to migrate into the lesion penumbra as well as extending processes to contralateral hemisphere through corpus callosum. The grafted cells were predominantly stained for immature neuronal but not astrocytic markers. In addition no abnormal aggregation of undifferentiated cells were observed in either groups. We are currently in the processing more brain sections for further unbiased quantification of the hNSC in PBBI.

    Conclusions: In this model, we concluded that there was robust engraftment of FDA-approved hNSCs observed up to 6 weeks with or without fibrin matrix, suggesting that this injury is conducive for repair.

    Patient Care: Lays a solid foundation to accelerate the translational process for its use in human PTBI.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Describe the role of stem cell therapy in TBI 2) TO learn the role of fibrin matrix in supporting neural stem cell for survival.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy